机构:[1]Medical College, Guizhou University, Guiyang, China.[2]Zhongda Hospital, School of Life Sciences and Technology, Advanced Institute for Life and Health, Southeast University, Nanjing, China.[3]Medical School of Nanjing University, Nanjing, China.[4]School of Biomedical Engineering (Suzhou), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.[5]Department of Microbiology and Immunology, Shanxi Medical University, Taiyuan, Shanxi, China.[6]Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Taiyuan, China.广东省人民医院[7]Center for Immunology and Hematology, Department of Biotherapy and Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院
The function of PD-1/PD-L1 axis have been intensively studied for immune escape of various cancers. However, the underlying function of PD-L2 remains poorly understood. Here, we demonstrate that PD-L2 is majorly expressed in exosomes with surface localization by clear cell renal cell carcinoma (ccRCC) cells. Tumor cell-derived exosome PD-L2 (TDE-PD-L2) exhibits high expression compared with TDE-PD-L1 in various cancers. In the absence of adaptive immune, TDE-PD-L2 suppresses tumor growth and metastasis. Under immune competence condition, TDE-PD-L2 is hijacked by immune cells in a PD-1-dependent manner to systematically dampen function of T cells via the increased proportion of the regulatory T cells and the decreased proportion of cytotoxic CD8+ T cells in both tumor-infiltrating T cells and spleen. The effects of TDE-PD-L2 on tumor is restored by antibodies targeting PD-L2. Collectively, we demonstrate that PD-1/TDE-PD-L2 axis systematically suppresses T cell functions, representing a potentially therapeutic strategy for ccRCC treatment.
基金:
National Natural Science Foundation of China (National Science Foundation of China) [82025029, 82150114, 32230036, 82025002]; National Natural Science Foundation of China; Fundamental Research Funds for the Central Universities [RF1028623018, RF1028624082, RF1028623022]; Start-up Research Fund of Southeast University [XDB29040103]; Strategic Pilot Science and Technology Project of Chinese Academy of Sciences [2023M730741]; China Postdoctoral Science Foundation [2022ZB106]; Jiangsu Funding Program for Excellent Postdoctoral Talent
第一作者机构:[1]Medical College, Guizhou University, Guiyang, China.[2]Zhongda Hospital, School of Life Sciences and Technology, Advanced Institute for Life and Health, Southeast University, Nanjing, China.
通讯作者:
推荐引用方式(GB/T 7714):
Liu Tongfeng,Cheng Shuwen,Peng Bo,et al.PD-L2 of tumor-derived exosomes mediates the immune escape of cancer cells via the impaired T cell function[J].CELL DEATH & DISEASE.2024,15(11):doi:10.1038/s41419-024-07191-7.
APA:
Liu, Tongfeng,Cheng, Shuwen,Peng, Bo,Zang, Haojing,Zhu, Xiaofeng...&Gao, Shan.(2024).PD-L2 of tumor-derived exosomes mediates the immune escape of cancer cells via the impaired T cell function.CELL DEATH & DISEASE,15,(11)
MLA:
Liu, Tongfeng,et al."PD-L2 of tumor-derived exosomes mediates the immune escape of cancer cells via the impaired T cell function".CELL DEATH & DISEASE 15..11(2024)